SBFM

Over the past six months, Sunshine Biopharma's stock has been impacted by several events. The company reported fiscal 2025 revenue of $36.3 million, a 4.1% increase, with a net loss of $5.98 million, and Q4 2025 EPS missed analysts' expectations. Health Canada authorized the marketing of Domperidone, and the company launched Doxycycline and Pravastatin in October 2025. Director Natan David received 100,000 SBFM shares in a stock award in April 2026. Shareholders have experienced substantial dilution, with total shares outstanding growing by 34.9%. The company's share price has been highly volatile, and as of May 4, 2026, the stock price was $1.09 per share, a 14.17% decline from May 5, 2025.